|Table of Contents|

Discordance of the expression of ER，PR and HER-2 between primary breast cancer and recurrent metastatic of breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 01
Page:
64-66
Research Field:
Publishing date:

Info

Title:
Discordance of the expression of ER，PR and HER-2 between primary breast cancer and recurrent metastatic of breast cancer
Author(s):
Tian Qingqing1; Liu Lihong1; Yuan Jingping2
1.Department of Pathology，the Central Hospital of Wuhan，Tongji Medical College，Huazhong University of Science and Technology，Hubei Wuhan 430014，China；2.Department of Pathology，Renmin Hospital of Wuhan University，Hubei Wuhan 430060，China.
Keywords:
breast cancer; primary; recurrent metastatic
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2019.01.016
Abstract:
Objective：To investigate discordance of ER，PR and HER-2 between primary and recurrent metastatic of breast cancer.Methods：ER，PR and HER-2 expression in 68 cases with primary breast cancer and the corresponding recurrent metastatic cancer were detected by immunohistochemical EnVision method.Results：The positive rates of ER，PR and HER-2 in recurrent metastatic cancer were 26.47%，39.71%，33.82%，obviously reduced compared with primary 58.82%，55.88%，36.76%.The difference of ER was statistically significant(P<0.05),while the difference of PR and HER-2 was not significant(P>0.05).Conclusion：The expression of ER，PR and HER-2 in recurrent metastatic breast cancer was obviously reduced than those in primary.ER，PR，HER-2 should be retested for recurrent metastatic breast cancer patients.

References:

[1]Harbeck N，Gnant M.Breast cancer［J］.Lancet，2017，389(10074)：1134-1150.
[2]Zhang BL，Song FJ.Genomics of breast cancer［J］.Chin J Clin Oncol 2014，41(3)：207-210.［张柏林，宋丰举.乳腺癌基因组学研究进展［J］.中国肿瘤临床，2014，41(3)：207-210.］
[3]Breast Cancer HER2 Test Guide2014) Writing Group.Breast Cancer HER2 Test Guide(2014)［J］.Chin J Pathol，2014，43(4)：262-267.［《乳腺癌HER2检测指南（2014版）》编写组.乳腺癌HER2检测指南（2014版）［J］.中华病理学杂志，2014，43(4)：262-267.］
[4]Hammond ME，Hayes DF，Dowsett M，et al.American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer［J］.J Clin Oncol，2010，28(21)：2784-2795.
[5]Chen CC，Xu PQ.Research progress of local recurrence after breast cancer surgery［J］.Chinese Journal of General Practice，2013，11(5)：770-771.［陈春春，许培权.乳腺癌术后局部复发研究进展［J］.中华全科医学，2013，11(5)：770-771.］
[6]Deng Zhiping，Zhu Jiang，Ma Ningqiang，et al.Discordance of the expression of ER，PR and HER-2 receptor statuses between primary breast cancer and recurrent focuses［J］.Modern Oncology，2011，19(8)：1562-1564.［邓智平，朱江，马宁强，等.乳腺癌ER、PR、HER-2在原发灶及复发转移灶中表达变化［J］.现代肿瘤医学，2011，19(8)：1562-1564.］
[7]Li WH，Zhang Y.Difference of ER，PR，HER-2，p53，Ki-67 expression in recurrence and/or metastasis compared to primary breast cancer［J］.J Clin Exp Pathol，2016，32(7)：727-730.［李文华，张莹.乳腺癌复发转移灶与原发灶中ER、PR、HER-2、p53、Ki-67的表达差异［J］.临床与实验病理学杂志，2016，32(7)：727-730.］
[8]Curtit E，Nerich V，Mansi L，et al.Discordances in estrogen receptor status，progesterone receptor status，and HER-2 status between primary breast cancer and metastasis［J］.Oncologist，2013，18(6)：667-674.
[9]Sun L，Yu DH，Sun SY，et al.Expressions of ER，PR，HER-2，COX-2，and VEGF in primary and relapsed/metastatic breast cancers［J］.Cell Biochem Biophys，2014，68(3)：511-516.
[10] Broom RJ，Tang P.Changes in estrogen receptor(ER)，progesteronereceptor(PR)，and HER2/neu status with time.Discordancerates between primary and metastatic breast pathology samples［J］.Am Society Clin Oncol，2007，3(1)：45-48.
[11]Lower EE，Glass E.HER-2/neu expression in primary and metastatic breast cancer［J］.Breast Cancer Res Treat，2009，113(2)：301-306.
[12]Loibl S，Gianni L.HER-2-positive breast cancer［J］.Lancet，2017，389(10087)：2415-2429.
[13]Denkert C，Liedtke C，Tutt A，et al.Molecular alterations in triple-negative breast cancer-the road to new treatment strategies［J］.Lancet，2017，389(10087)：2430-2442.

Memo

Memo:
武汉市科技计划项目（编号：2017060201010172）
Last Update: 2018-11-30